157 related articles for article (PubMed ID: 30519344)
1. Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer.
Mao LJ; Ding M; Xu K; Pan J; Yu H; Yang C
J Cancer; 2018; 9(23):4391-4397. PubMed ID: 30519344
[TBL] [Abstract][Full Text] [Related]
2. Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer.
Mao L; Yu H; Ma S; Xu Z; Wei F; Yang C; Zheng J
J Cancer; 2021; 12(6):1846-1852. PubMed ID: 33613773
[No Abstract] [Full Text] [Related]
3. Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis.
Mao LJ; Zhang J; Liu N; Fan L; Yang DR; Xue BX; Shan YX; Zheng JN
Tumour Biol; 2015 Nov; 36(11):9073-81. PubMed ID: 26084613
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma.
Yang C; Cao H; Liu N; Xu K; Ding M; Mao LJ
Drug Des Devel Ther; 2016; 10():3755-3761. PubMed ID: 27895465
[TBL] [Abstract][Full Text] [Related]
5. Combination Therapy of Prostate Cancer by Oncolytic Adenovirus Harboring Interleukin 24 and Ionizing Radiation.
Mao LJ; Kan Y; Li BH; Ma S; Liu Y; Yang DL; Yang C
Front Oncol; 2020; 10():421. PubMed ID: 32318337
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenovirus carrying SPAG9-shRNA enhanced the efficacy of docetaxel for advanced prostate cancer.
Lu M; Xu Z; Wei F; Wang J; Ma S; Kan Y; Li B; Wu C; Mao L
Anticancer Drugs; 2022 Feb; 33(2):142-148. PubMed ID: 34561997
[TBL] [Abstract][Full Text] [Related]
7. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
[TBL] [Abstract][Full Text] [Related]
8. Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice.
He B; Huang X; Liu X; Xu B
Mol Biol Rep; 2013 Sep; 40(9):5397-405. PubMed ID: 23666064
[TBL] [Abstract][Full Text] [Related]
9. Combination of oncolytic adenovirus ZD55 harboring TRAIL-IETD-MnSOD and cytokine-induced killer cells against lung cancer.
Jiang R; Zhang Z; Liao X; Huang L; Liao Y; Deng W
Ann Transl Med; 2021 Oct; 9(20):1527. PubMed ID: 34790733
[TBL] [Abstract][Full Text] [Related]
10. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.
Zhao L; Gu J; Dong A; Zhang Y; Zhong L; He L; Wang Y; Zhang J; Zhang Z; Huiwang J; Qian Q; Qian C; Liu X
Hum Gene Ther; 2005 Jul; 16(7):845-58. PubMed ID: 16000066
[TBL] [Abstract][Full Text] [Related]
11. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy.
Cai Y; Liu X; Huang W; Zhang K; Liu XY
Acta Biochim Biophys Sin (Shanghai); 2012 Jun; 44(6):535-43. PubMed ID: 22635106
[TBL] [Abstract][Full Text] [Related]
13. Synergistic suppression effect on tumor growth of ovarian cancer by combining cisplatin with a manganese superoxide dismutase-armed oncolytic adenovirus.
Wang S; Shu J; Chen L; Chen X; Zhao J; Li S; Mou X; Tong X
Onco Targets Ther; 2016; 9():6381-6388. PubMed ID: 27799786
[TBL] [Abstract][Full Text] [Related]
14. Optimization of the Administration Strategy for the Armed Oncolytic Adenovirus ZD55-IL-24 in Both Immunocompromised and Immunocompetent Mouse Models.
Hu HJ; Liang X; Li HL; Wang HY; Gu JF; Sun LY; Xiao J; Hu JQ; Ni AM; Liu XY
Hum Gene Ther; 2021 Dec; 32(23-24):1481-1494. PubMed ID: 34155929
[TBL] [Abstract][Full Text] [Related]
15. Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer.
Zhang Y; Qin X; Zhang Y; Zhao L; Wang Y; Liu X; Yao L
J Cancer Res Clin Oncol; 2008 Feb; 134(2):219-26. PubMed ID: 17632733
[TBL] [Abstract][Full Text] [Related]
16. VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis.
Xiao T; Fan JK; Huang HL; Gu JF; Li LY; Liu XY
Cell Res; 2010 Mar; 20(3):367-78. PubMed ID: 19918267
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer.
Ma S; Qu W; Mao L; Zhu Z; Jia L; Zhao L; Zheng X
Oncol Rep; 2012 May; 27(5):1443-50. PubMed ID: 22294034
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.
Li Y; Zhuo B; Yin Y; Han T; Li S; Li Z; Wang J
Biochem Biophys Res Commun; 2017 Sep; 491(1):134-139. PubMed ID: 28711493
[TBL] [Abstract][Full Text] [Related]
19. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1.
Zhang Z; Zou W; Wang J; Gu J; Dang Y; Li B; Zhao L; Qian C; Qian Q; Liu X
Mol Ther; 2005 Apr; 11(4):553-62. PubMed ID: 15771958
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis.
Zheng JN; Pei DS; Mao LJ; Liu XY; Sun FH; Zhang BF; Liu YQ; Liu JJ; Li W; Han D
Cancer Gene Ther; 2010 Jan; 17(1):28-36. PubMed ID: 19498459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
